Comparison of daily low dose cisplatin versus weekly cisplatin concurrently with radiotherapy during head and neck cancer

Leena Gupta Ligu; Vikas Jagtap; Monchmee Bhattacharya

doi:10.18231/j.ijmpo.2020.029

journal article Sep 15, 2020

Comparison of daily low dose cisplatin versus weekly cisplatin concurrently with radiotherapy during head and neck cancer

Leena Gupta Ligu Vikas Jagtap Monchmee Bhattacharya

IP International Journal of Medical Paediatrics and Oncology Vol. 6 No. 3 pp. 125-130 · IP Innovative Publication Pvt Ltd

View at Publisher Save 10.18231/j.ijmpo.2020.029

Abstract

Head and neck cancers can arise in the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid, and salivary glands and include a variety of histopathologic tumours. Squamous cell cancer (SCC) is the most common pathological type of head and neck cancer.This is prospective, Observational and comparative study.The diagnosis of untreated squamous cell carcinoma of the head and neck region, i.e., oral cavity, oropharynx, hypopharynx, or larynx in advanced stage III, IVA or IVB SCCHN was confirmed by a radiation oncologist prior to the initiation of the treatment. Patients were considered to comply with radiation treatment if they completed 70 Gy within 45 days. Chemotherapy compliance (six cycles in weekly or 28–30 cycles in daily cisplatin) were 63% and 73%, respectively. The primary reason for noncompliance toward chemotherapy (37% vs. 27% in weekly vs. daily Cisplatin studies, respectively) was due to the development of excessive toxicity. This also included those who left treatment midway (due to any reason) or died during therapy.Therefore, if an intensified treatment protocol has to be used, i.e. modest acceleration along with either “weekly” or “daily” cisplatin, both can be used, provided patients are selected properly and due attention is paid to timely and adequate supportive care.

Topics

No keywords indexed for this article. Browse by subject →

References

22

[1]

Le X, Hanna E Y, Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined.Ann Transl Med 2018;6(11):229 10.21037/atm.2018.05.10

[2]

Seiwert T Y, Salama J K, Vokes E E, Chemoradiotherapy paradigm in Head & neck cancer.Nat Clin Pract Oncol 2007;4:156-71 10.1038/ncponc0750

[3]

Laramore G.E., Scott C.B., Al-Sarraf M., Haselow R.E., Ervin T.J., Wheeler R., Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034.Int J Radiat Oncol Biol Phys 1992;23(4):705-13 10.1016/0360-3016(92)90642-u

[4]

Vokes E E, Weichselbaum R R, Lippman S M, Hong W K, Head and Neck Cancer.N Engl J Med 1993;328(3):184-94 10.1056/nejm199301213280306

[5]

Bloom C, Just N, Remy H, Black M, Rossignol M, Laryngeal cancer: is computed tomography a valuable imaging technique? A retrospective analysis.Can Assoc Radiol J 1998;49:370-7

[6]

Haughey Bruce H., Arfken Cynthia L., Gates George A., Harvey Joseph, Meta-Analysis of Second Malignant Tumors in Head and Neck Cancer: The Case for an Endoscopic Screening Protocol.Ann Otol, Rhinol Laryngology 1992;101(2):105-12 10.1177/000348949210100201

[7]

Guardiola E, Pivot X, Dassonville O, Poissonnet G, Marcy Perre-Yves, Otto J, Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?.Cancer 2004;101(9):2028-33 10.1002/cncr.20623

[8]

Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.Lancet Oncol 2013;14(3):257-64 10.1016/s1470-2045(13)70011-1

[9]

Rodriguez Cristina P., Adelstein David J., Survival Trends in Head and Neck Cancer: Opportunities for Improving Outcomes.Oncologist 2010;15(9):921-3 10.1634/theoncologist.2010-0237

[10]

Traynor A M, Richards G M, Hartig G K, Khuntia D, Cleary J F, Wiederholt P A, Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience.Head Neck 2009;32:599-606 10.1002/hed.21224

[11]

Homma A., Inamura N., Oridate N., Suzuki S., Hatakeyama H., Mizumachi T., Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer.Japanese J Clin Oncol 2011;41(8):980-6 10.1093/jjco/hyr086

[12]

Newlin H E, Amdur R J, Riggs C E, Morris C G, Kirwan J M, Mendenhall W M, Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.Cancer 2010;116(19):4533-40 10.1002/cncr.25189

[13]

Sharma A., Mohanti B.K., Thakar A., Bahadur S., Bhasker S., Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial.Ann Oncol 2010;21(11):2272-7 10.1093/annonc/mdq219

[14]

Lal P, Gupta P K, Bajpai R, Goel A, Yadav R, Verma M, Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer.South Asian J Cancer 2016;5(2):80-4 10.4103/2278-330x.181647

[15]

Rades D, Seidl D, Janssen S, Strojan P, Karner K, Bajrovic A, Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers.Eur Arch Oto-Rhino-Laryngology 2017;274(2):1021-7 10.1007/s00405-016-4326-5

[16]

Kaneko T., Tada Y., Maruya S., Takeishi E., Miura K., Masubuchi T., Intra-arterial chemoradiation therapy with weekly low-dose cisplatin for squamous cell carcinoma of the maxillary sinus.Int J Oral Maxillofac Surg 2015;44(6):697-704 10.1016/j.ijom.2015.03.009

[17]

Maeda S, Sugiura T, Saikawa Y, Kubota T, Otani Y, Kumai K, Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.Cancer Sci 2004;95(8):679-84 10.1111/j.1349-7006.2004.tb03329.x

[18]

Yabuuchi H, Kuroiwa T, Tajima T, Tomita K, Ochiai N, Kawamoto K, Efficacy of Intra-arterial Infusion Therapy Using a Combination of Cisplatin and Docetaxel for Recurrent Head and Neck Cancers Compared with Cisplatin Alone.Clin Oncol 2003;15(8):467-72 10.1016/j.clon.2003.07.003

[19]

Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T, Nakahara R, Arterial Chemoradiotherapy for Locally Advanced Tongue Cancer: Analysis of Retrospective Study of Therapeutic Results in 88 Patients.Int J Radiat Oncol Biol Physics 2008;72(4):1090-1100 10.1016/j.ijrobp.2008.02.021

[20]

Shah J P, Gil Z, Current concepts in management of oral cancer – Surgery.Oral Oncol 2009;45(4-5):394-401 10.1016/j.oraloncology.2008.05.017

[21]

Iqbal M, Chaw C, Kovarik J, Aslam S, Jackson A, Kelly J, Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival.Int Arch Otorhinolaryngol 2017;21(02):171-7 10.1055/s-0036-1594020

[22]

Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T, Nakahara R, Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in134 cases.Br J Cancer 2008;98(6):1039-45 10.1038/sj.bjc.6604272

Metrics

0

Citations

22

References

Details

Published: Sep 15, 2020
Vol/Issue: 6(3)
Pages: 125-130

Authors

Monchmee Bhattacharya

Cite This Article

Leena Gupta Ligu, Vikas Jagtap, Monchmee Bhattacharya (2020). Comparison of daily low dose cisplatin versus weekly cisplatin concurrently with radiotherapy during head and neck cancer. IP International Journal of Medical Paediatrics and Oncology, 6(3), 125-130. https://doi.org/10.18231/j.ijmpo.2020.029

Comparison of daily low dose cisplatin versus weekly cisplatin concurrently with radiotherapy during head and neck cancer

You May Also Like